Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

The Involvement of the Mammalian Target of Rapamycin, Protein Tyrosine Phosphatase 1b and Dipeptidase 4 Signaling Pathways in Cancer and Diabetes: A Narrative Review

How is the AKT/mTOR Pathway Involved in Cell Migration and Invasion?

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

mTOR pathway: A key player in diabetic nephropathy progression and therapeutic targets

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges

Targeting PI3K/Akt/mTOR Signaling in Cancer

Targeting PI3K in cancer: mechanisms and advances in clinical trials

Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

mTOR Complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy

The Interlinking Metabolic Association between Type 2 Diabetes Mellitus and Cancer: Molecular Mechanisms and Therapeutic Insights

PI3K/AKT/mTOR and PD‐1/CTLA‐4/CD28 pathways as key targets of cancer immunotherapy (Review)

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.